← All organizations
Highest phase reached
Phase 3
First clinical trial
Apr 1, 2007First marketed drug
Jun 1, 2021First NDA
Jun 1, 2021Last known activity
Jul 12, 2023
Timeline
1990s
- Jun 1, 1999
Scynexis, Inc.— Founded
2020s
- Jun 1, 2021
Ibrexafungerp— Marketing Organization
- Jun 1, 2021
Ibrexafungerp— NDA Organization
- Jun 1, 2021
Ibrexafungerp— NDA Secondary Org
Drugs by trial phase (9 distinct, 18 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Indications
Studied for
- Aspergillosis
- Aspergillosis, Allergic Bronchopulmonary
- Blastomycosis
- Candidemia
- Candidiasis
- Candidiasis, Chronic Mucocutaneous
- Candidiasis, Invasive
- Candidiasis, Vulvovaginal
- Coccidioidomycosis
- Coccidiosis
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Histoplasmosis
- Infections
- Invasive Pulmonary Aspergillosis
- Mycoses
- Pulmonary Aspergillosis
- Vulvovaginitis
Marketed drugs (1)
Recent trials (27)
- NCT06954493Lead sponsorPhase 1Jul 12, 2023
- NCT05668429Lead sponsorPhase 1Dec 31, 2022
- NCT05178862Lead sponsorPhase 3Aug 3, 2022
- NCT05399641Study directorPhase 3May 1, 2022
- NCT05399641Lead sponsorPhase 3May 1, 2022
- NCT04307082Study directorPhase 1Dec 5, 2019
- NCT04307082Lead sponsorPhase 1Dec 5, 2019
- NCT04092751Lead sponsorPhase 1Oct 22, 2019
- NCT04092725Lead sponsorPhase 1Sep 22, 2019
- NCT04029116Study directorPhase 3Aug 31, 2019
- NCT04029116Lead sponsorPhase 3Aug 31, 2019
- NCT03987620Lead sponsorPhase 3Jun 7, 2019
- NCT03734991Lead sponsorPhase 3Jan 4, 2019
- NCT03734991Study directorPhase 3Jan 4, 2019
- NCT03672292Lead sponsorPhase 2Oct 31, 2018
Details
- Founded
- Durham, NC, US Jun 1, 1999
- First NDA
- Jun 1, 2021
- Last known activity
- Jul 12, 2023
Designations held
- Fast track
- Priority review